Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 3Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Recurrence 1Gliosarcoma 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 83Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
rilotumumab × CNS × Clear all
NCT01113398 2015-12-10

AMG 102 and Avastin for Recurrent Malignant Glioma

Duke University

Phase 2 Completed
36 enrolled 9 charts
CNSSarcoma

Glioblastoma, Glioma, Recurrence, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡